` TECX (AVROBIO Inc) vs S&P 500 Comparison - Alpha Spread

TECX
vs
S&P 500

Over the past 12 months, TECX has underperformed S&P 500, delivering a return of -56% compared to the S&P 500's +12% growth.

Stocks Performance
TECX vs S&P 500

Loading
TECX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TECX vs S&P 500

Loading
TECX
S&P 500
Difference
www.alphaspread.com

Performance By Year
TECX vs S&P 500

Loading
TECX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
AVROBIO Inc vs Peers

S&P 500
TECX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

AVROBIO Inc
Glance View

Market Cap
369.8m USD
Industry
Biotechnology

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.

TECX Intrinsic Value
7.52 USD
Overvaluation 62%
Intrinsic Value
Price
Back to Top